By Harald Nusser (originally posted on LinkedIn) Harald Nusser is Global Head of Novartis Access, a Sandoz-operated portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month.
In early June, Novartis Access held a stakeholder dialogue in conjunction with the World Health Assembly. It was the second event with WHA, and the goal was to follow-up on the discussion started at the launch of Novartis Access in November 2015 on how to address the burden of non-communicable diseases (NCDs) in lower-income countries.
Following the event, Dr. Nusser published a LinkedIn post in which he described the actions needed to tackle NCDs, making the point that innovative solutions are needed to address this global burden.
In addition, This Week in Global Health, a weekly program that gives a brief overview of current events and topics in global health news, interviewed the panelists, including Dr. Harald Nusser, Global Head of Novartis Access. Dr. Nusser spoke about the rationale for Novartis Access, the major disease burden of non-communicable diseases (NCDs), and why Novartis Access focuses its work on cardiovascular diseases, diabetes, respiratory diseases, and breast cancer specifically.